KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Short-term Investments (2016 - 2025)

Rigel Pharmaceuticals has reported Short-term Investments over the past 16 years, most recently at $114.4 million for Q4 2025.

  • Quarterly results put Short-term Investments at $114.4 million for Q4 2025, up 455.89% from a year ago — trailing twelve months through Dec 2025 was $114.4 million (up 455.89% YoY), and the annual figure for FY2025 was $114.4 million, up 455.89%.
  • Short-term Investments for Q4 2025 was $114.4 million at Rigel Pharmaceuticals, up from $88.6 million in the prior quarter.
  • Over the last five years, Short-term Investments for RIGL hit a ceiling of $114.4 million in Q4 2025 and a floor of $9.4 million in Q3 2024.
  • Median Short-term Investments over the past 5 years was $32.6 million (2022), compared with a mean of $48.4 million.
  • Biggest five-year swings in Short-term Investments: plummeted 77.82% in 2023 and later soared 840.45% in 2025.
  • Rigel Pharmaceuticals' Short-term Investments stood at $106.1 million in 2021, then plummeted by 68.19% to $33.7 million in 2022, then dropped by 28.45% to $24.1 million in 2023, then dropped by 14.79% to $20.6 million in 2024, then soared by 455.89% to $114.4 million in 2025.
  • The last three reported values for Short-term Investments were $114.4 million (Q4 2025), $88.6 million (Q3 2025), and $55.0 million (Q2 2025) per Business Quant data.